<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7612148</journal-id>
<journal-id journal-id-type="pubmed-jr-id">6787</journal-id>
<journal-id journal-id-type="nlm-ta">Psychoneuroendocrinology</journal-id>
<journal-id journal-id-type="iso-abbrev">Psychoneuroendocrinology</journal-id>
<journal-title-group>
<journal-title>Psychoneuroendocrinology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0306-4530</issn>
<issn pub-type="epub">1873-3360</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29734055</article-id>
<article-id pub-id-type="pmc">5995655</article-id>
<article-id pub-id-type="doi">10.1016/j.psyneuen.2018.04.019</article-id>
<article-id pub-id-type="manuscript">NIHMS966011</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Kynurenine pathway metabolic balance influences microglia activity: targeting kynurenine monooxygenase to dampen neuroinflammation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Garrison</surname>
<given-names>Allison M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Parrott</surname>
<given-names>Jennifer M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tuñon</surname>
<given-names>Arnulfo</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Delgado</surname>
<given-names>Jennifer</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Redus</surname>
<given-names>Laney</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>O'Connor</surname>
<given-names>Jason C.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Pharmacology, The University of Texas Health Science Center at San Antonio</aff>
<aff id="A2">
<label>2</label>The Center for Biomedical Neuroscience, School of Medicine, The University of Texas Health Science Center at San Antonio</aff>
<aff id="A3">
<label>3</label>Audie L. Murphy VA Hospital, South Texas Veterans Health System, San Antonio, Texas</aff>
<author-notes>
<corresp id="FN1">Address correspondence to. Jason C. O'Connor, Ph.D., 422D Medical Building MC-7764, 7703 Floyd Curl Dr., San Antonio, TX 78229-3900. Telephone: (210) 567-4232, Fax: (210) 567-4300, <email>oconnorj@uthscsa.edu</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p><bold>Conflict of Interest Statement</bold>: Dr. O'Connor has had previous consulting agreements with Lundbeck Research USA and Janssen Research and Development, LLC unrelated to the work contained in this manuscript.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>9</day>
<month>5</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>22</day>
<month>4</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>8</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>8</month>
<year>2019</year>
</pub-date>
<volume>94</volume>
<fpage>1</fpage>
<lpage>10</lpage>
<!--elocation-id from pubmed: 10.1016/j.psyneuen.2018.04.019-->
<abstract>
<p id="P1">Chronic stress or inflammation increases tryptophan metabolism along the kynurenine pathway (KP), and the generation of neuroactive kynurenine metabolites contributes to subsequent depressive-like behaviors. Microglia regulate KP balance by preferentially producing oxidative metabolites, including quinolinic acid. Research has focused on the interplay between cytokines and HPA axis-derived corticosteroids in regulating microglial activity and effects of KP metabolites directly on neurons; however, the potential role that KP metabolites have directly on microglial activity is unknown. Here, murine microglia were stimulated with lipopolysaccharide(LPS). After 6 hours, mRNA expression of interleukin(IL)-1β, IL-6, tumor necrosis factor(TNF)-α and inducible nitric oxide synthase(iNOS) was dose-dependently increased along with the rate-limiting enzymes for oxidative KP metabolism, indoleamine-2,3-dioxygenase(IDO)-1 and kynurenine 3-monooxygenase(KMO). By 24 hours post-LPS, kynurenine and quinolinic acid in the media was elevated. Inhibiting KMO with Ro 61-8048 during LPS challenge attenuated extracellular nitrite accumulation and expression of KMO and TNF-α in response to LPS. Similarly, primary microglia isolated from KMO<sup>-/-</sup> mice exhibited a significantly reduced pro-inflammatory response to LPS compared to WT controls. To determine whether the substrate (kynurenine) or end product (quinolinic acid) of KMO-dependent metabolism modulates the LPS response, microglia were treated with increasing concentrations of L-kynurenine or quinolinic acid in combination with LPS or saline. Interestingly, quinolinic acid did not impact the microglial LPS response. However, L-kynurenine had dose-dependent inhibitory effect on the LPS response. These data are the first to show an anti-inflammatory effect of KMO inhibition on microglia during immune challenge and suggest that KP metabolic balance may play a direct role in regulating microglia activity.</p>
</abstract>
<kwd-group>
<kwd>microglia</kwd>
<kwd>kynurenine</kwd>
<kwd>quinolinic acid</kwd>
<kwd>inflammation</kwd>
<kwd>cytokines</kwd>
<kwd>kynurenine metabolism</kwd>
<kwd>microglia</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>